UBS AM
CERE

UBS AM’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

UBS AM’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-90,932
Closed -$3.72M – 2887
2024
Q2 		$3.72M Buy
90,932
+6,095
+7% +$254K ﹤0.01% 1657
2024
Q1 		$3.59M Buy
84,837
+193
+0.2% +$8.11K ﹤0.01% 1406
2023
Q4 		$3.59M Buy
84,644
+13,697
+19% +$394K ﹤0.01% 1411
2023
Q3 		$1.55M Buy
70,947
+9,982
+16% +$250K ﹤0.01% 1740
2023
Q2 		$1.49M Hold
60,965
– – ﹤0.01% 1818
2023
Q1 		$1.49M Buy
60,965
+9,649
+19% +$283K ﹤0.01% 1818
2022
Q4 		$1.62M Buy
51,316
+1,348
+3% +$38K ﹤0.01% 1632
2022
Q3 		$1.41M Sell
49,968
-12,227
-20% -$364K ﹤0.01% 1776
2022
Q2 		$1.64M Buy
62,195
+28,373
+84% +$806K ﹤0.01% 1706
2022
Q1 		$1.18M Hold
33,822
– – ﹤0.01% 2047
2021
Q4 		$1.1M Buy
33,822
+550
+2% +$19.4K ﹤0.01% 2165
2021
Q3 		$982K Buy
+33,272
New +$934K ﹤0.01% 2175

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

UBS AM's CERE Position: Q3 2024 in Review

UBS AM sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 90,932 shares — an estimated $3.72M sold.

UBS AM first reported a position in CERE in Q3 2021 and held it in 12 quarters. The position peaked at $3.72M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • UBS AM reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • UBS AM sold 90,932 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $3.72M.
  • UBS AM first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 12 quarters.
  • UBS AM's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $3.72M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on UBS AM's 13F filing for Q3 2024, filed 14 Nov 2024.